Volume 5.25 | Jul 8

Hematopoiesis News 5.25 July 8, 2014
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Researchers Identify Events Causing Bone Marrow Inflammation Leading to Blood Disorders
Like a line of falling dominos, a cascade of molecular events in the bone marrow produces high levels of inflammation that disrupt normal blood formation and lead to potentially deadly disorders including leukemia, a research team has reported. [Press release from the Indiana University School of Medicine discussing online prepublication in Cell Stem Cell] Press Release | Abstract | Graphical Abstract
Request Sample: ReLeSR™, Easy Passaging Through Selective Detachment of hPSCs
PUBLICATIONS (Ranked by impact factor of the journal)
The Rothmund-Thomson Syndrome Helicase RECQL4 Is Essential for Hematopoiesis
Scientists demonstrate that somatic deletion of Recql4 causes a rapid bone marrow failure in mice that involves cells from across the myeloid, lymphoid, and, most profoundly, erythroid lineages. [J Clin Invest] Full Article

Preclinical Evaluation of Echinomycin: Therapeutic Efficacy in Relapsed Acute Myeloid Leukemia without Adverse Effects on Host Hematopoietic Stem Cells
Investigators used a mouse model of relapsed acute myeloid leukemia (AML) to explore whether the HIF1α inhibitor Echinomycin can be used to treat relapsed AML without affecting host hematopoietic stem cells. [Blood] Abstract

Serpin Spi2A as a Novel Modulator of Hematopoietic Progenitor Cell Formation
Via loss-of-function studies, scientists define roles for an hematopoietin-regulated Serpina3g/Spi2A intracellular serpin during granulomyelocytic, B-cell and HSC formation. In granulomyelocytic progenitors, GMCSF strongly induced Serpina3g expression with Stat5-dependency. [Stem Cells] Abstract

Nitric Oxide-Induced Murine Hematopoietic Stem Cell Fate Involves Multiple Signaling Proteins, Gene Expression and Redox Modulation
The direct role of nitric oxide (NO), a reactive nitrogen species, in the modulation of hematopoiesis was investigated using two sources of NO, one produced by endothelial cells stimulated with carbachol in vitro and another using the NO-donor SNAP in vivo. [Stem Cells] Abstract

Potent Cooperation between the NUP98-NSD1 Fusion and FLT3-ITD Mutation in Acute Myeloid Leukemia Induction
The NUP98-NSD1 fusion, product of the t(5;11)(q35;p15.5) chromosomal translocation, is one of the most prevalent genetic alterations in cytogenetically normal pediatric acute myeloid leukemias and is associated with poor prognosis. Expression of NUP98-NSD1 provided mouse strain-dependent, aberrant self-renewal potential to bone marrow progenitor cells. [Haematologica] Full Article

Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 Marks Short-Term Hematopoietic Stem and Progenitor Cells during Mouse Embryonic Development
The authors report the detection of Lgr5 expression in hematopoietic stem and progenitor cells (HSPCs) in the aorta-gonad-mesonephros and fetal liver. They also found that a portion of Lgr5+ cells expressed Runx-1 genes that are critical for the ontogeny of HSPCs. [J Biol Chem] Abstract | Full Article

Cytokine-Regulated GADD45G Induces Differentiation and Lineage Selection in Hematopoietic Stem Cells
Investigators identified the tumor suppressor GADD45G as an instructor of long-term repopulating hematopoietic stem cell differentiation under the control of differentiation-promoting cytokine receptor signaling. [Stem Cell Rep] Full Article | Graphical Abstract


Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype
Myeloablative allogeneic hematopoietic stem cell transplantation is curative for children with severe sickle cell disease, but toxicity may be prohibitive for adults. Researchers aimed to determine the efficacy, safety, and outcome on end-organ function with this low-intensity regimen for sickle cell phenotype with or without thalassemia. [JAMA] Full Article | Press Release | Video

Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial
High-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation (HSCT) have shown efficacy in systemic sclerosis in Phase I and small Phase II trials. Investigators compared efficacy and safety of HSCT vs 12 successive monthly intravenous pulses of cyclophosphamide. [JAMA]
Abstract | Press Release

Results from a Clofarabine-Busulfan Containing Reduced-Toxicity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: The Phase II Prospective CLORIC Trial
Researchers prospectively evaluated the safety and efficacy of a clofarabine, intravenous busulfan and antithymocyte globulin-based reduced-toxicity conditioning regimen before allogeneic stem cell transplantation. [Haematologica] Abstract | Full Article

Cell Culture World Congress Asia 2014
Regulation of Hematopoietic and Leukemic Stem Cells by the Immune System
Many immune mechanisms that evolved to activate emergency hematopoiesis during infection may actually contribute to the expansion and differentiation of leukemic stem cells (LSCs), promoting leukemia progression. In this review, the authors summarize mechanisms by which the immune system regulates hematopoietic stem cells and LSCs. [Cell Death Differ] Full Article

Visit our reviews page to see a complete list of reviews in the hematology research field.

Fraunhofer Life Science Symposium
Amgen Receives FDA Breakthrough Therapy Designation for Investigational BiTE® Antibody Blinatumomab in Acute Lymphoblastic Leukemia
Amgen announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational bispecific T cell engager (BiTE®) antibody blinatumomab, for adults with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia, a rapidly progressing cancer of the blood and bone marrow. [Amgen Inc.] Press Release

FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq™ (Belinostat) for Injection
Spectrum Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of Beleodaq™ for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. [Spectrum Pharmaceuticals] Press Release

University of Pennsylvania’s Personalized Cellular Therapy for Leukemia Receives FDA’s Breakthrough Therapy Designation
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration’s Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia. The investigational therapy, known as CTL019, is the first personalized cellular therapy for the treatment of cancer to receive this classification. [Penn Medicine] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Advances in Stem Cell Research 2014
September 16-17, 2014

Visit our events page to see a complete list of events in the hematology community.
NEW PhD Student – Development and Regulation of Innate Immunity (Lund University)

NEW Biologist – Hypoxia Signaling in Myeloproliferative Neoplasms (University Hospital Aachen)

NEW Research Associate – Transcriptional/Epigenetic Changes and Their Roles in Normal and Malignant Hematopoietic Stem Cell Development (King’s College London)

NEW PhD Student – The Hematopoietic Niches in Bone (KU Leuven)

Scientific Manager – hES and iPS Cell Lines to Model Normal Hematopoiesis and Related Blood Diseases (St. Jude Children’s Research Hospital)

Postdoctoral Research Fellow – Cardiovascular Immunology / Hematology (Massachusetts General Hospital)

Research Associate – Hematopoietic and Leukemic Stem Cells (Shanghai Jiao-Tong University School of Medicine)

Clinical HSCT Faculty Position – Pediatric Hematology-Oncology (University of Wisconsin School of Medicine)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us